



DBV Technologies signs strategic agreement with Assistance Publique-Hôpitaux de Paris (AP-HP) office of technology transfer and industrial partnerships

Strategic agreement signed in advance of DBV Technologies U.S. Phase I peanut allergy trial

15 April 2009, Paris, France – DBV Technologies (DBV), a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy, announced today it has signed a strategic agreement with the Assistance Publique-Hôpitaux de Paris' Office of Technology Transfer and Industrial Partnerships.

The agreement follows DBV Technologies' success with its marketed DiallerTest® Milk, a product designed specifically for the diagnosis of cow's milk protein allergy in infants, as well as progress made with its Epicutaneous Specific Immunotherapy (EPIT) and its unique non-invasive epicutaneous delivery technology platform, VIASKIN®.

Although specific terms were not disclosed, the strategic agreement clarifies royalty streams and developmental milestones. The agreement is of strategic importance as DBV Technologies works toward the initiation of its EPIT Phase I study for peanut allergy desensitisation in the U.S.

Commenting on the agreement, Jean François Biry, Chairman and CEO of DBV Technologies, said, "Our early success with DiallerTest® and progress with our EPIT programme would not have been possible without the support of the Assistance Publique-Hôpitaux de Paris. We are pleased to have signed this agreement as we move towards our Phase I in peanut allergy desensitisation therapy."